Compare Cytokinetics Inc (CYTK) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Extra Space Storage, Inc. — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Extra Space Storage, Inc. trades at $134.05 (market cap $28.12B). The key difference: Extra Space Storage, Inc. is far larger — about 3.3× Cytokinetics Inc's market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Extra Space Storage, Inc. for 108 Days on average.
| CYTK | EXR | |
|---|---|---|
Market Cap | $8.62B | $28.12B |
Volume | 2,594,626 | 2,595,579 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $152.85 |
52-Week Low | $54.76 | $126.67 |
Typical Hold Time | 19 Days | 108 Days |
Enterprise Value | $8.72B | $41.84B |
Dividend Yield | — | 4.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
EXR trades at $133.3, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin improved to 27.79%. Analyst consensus is split evenly between Buy and Hold, with a $158.33 price target suggesting upside. Recent news highlights leadership transition and institutional buying interest.
Outlook is mixed: solid fundamentals and analyst targets support growth, but technical weakness and high valuation ratios pose risks. Investors should weigh steady cash flow and dividend yield against debt levels and market sentiment shifts ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
